Ranked by 2024 Global Sales: 1 Ozempic (semaglutide) $16.7 Bn | Novo Nordisk 2 Mounjaro (tirzepatide) $11.5 Bn | Eli Lilly 3 Jardiance (empagliflozin) $9.5 Bn | Boehringer Ingelheim & Eli Lilly 4 Forxiga (dapagliflozin) $7.7 Bn | AstraZeneca 5 Trulicity (dulaglutide) $5.3 Bn | Eli Lilly 6 Rybelsus (semaglutide) $3.2 Bn | Novo Nordisk 7 Humalog (insulin lispro) $2.3 Bn | Eli Lilly 8 NovoRapid (insulin aspart) $2.3 Bn | Novo Nordisk 9 Jentadueto / Trajenta (linagliptin) $1.8 Bn | Boehringer Ingelheim Lantus (insulin glargine) $1.7 Bn | Sanofi Key Insight: The dominance of incretin-based therapies underscores a clear industry shift toward multi-benefit, patient-centric treatments
BMP, bone morphogenetic protein
Indeed, a recent report that describes a case of osteoresorptive arsenic intoxication in a 47-year-old woman who had osteoporosis and had been exposed to arsenic as a child provides support for earlier animal studies that indicated that bone can be a reservoir of inorganic arsenic (arsenate) from which arsenic can be released later in life (Dani 2013)
Approximately 90% of hEDS patients suffer from GI challenges like reflux, gastroparesis, and irritable bowel syndrome (IBS)
MCT oil offers a range of documented health benefits, spanning energy production, weight management, cognitive function, appetite control, and support for ketosis all arising from the unique metabolic pathway of medium-chain triglycerides
curvatus HY7601 & Lactobacillus plantarum KY1032, and Akkermansia muciniphila
.jpg)
